Table of Contents

October 1, 2021; Volume 62,Issue 10

A

  1. Alazraki, Naomi

    1. Amnon (Amy) Piepsz, MD (1938–2021)
      Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;

  2. Allen-Auerbach, Martin

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  3. Ametamey, Simon M.

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  4. Anconina, Reut

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

  5. Antonarakis, Emmanuel S.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  6. Aparici, Carina Mari

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  7. Armstrong, Wesley R.

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

B

  1. Bahri, Shadfar

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  2. Bai, Chunmei

    1. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of <sup>68</sup>Ga-NODAGA-LM3 and <sup>68</sup>Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096

  3. Bal, Chandrasekhar

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  4. Ballal, Sanjana

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  5. Balm, Alfons J.M.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  6. Baratto, Lucia

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  7. Baroni, Luca

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  8. Bartolomei, Mirco

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  9. Bauder-Wüst, Ulrike

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  10. Baum, Richard P.

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  11. Bénard, François

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  12. Benešová, Martina

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  13. Berger, Danique M.S.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  14. Bernaudin, Myriam

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  15. Bernhardt, Peter

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  16. Berro, David Hassanein

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  17. Blackford, Amanda L.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  18. Blaufox, M. Donald

    1. Amnon (Amy) Piepsz, MD (1938–2021)
      Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;

  19. Bodei, Lisa

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  20. Boss, Silvan D.

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  21. Bracht, Thilo

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  22. Briganti, Alberto

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  23. Broos, Wouter A.M.

    1. Matched-Pair Comparison of <sup>18</sup>F-DCFPyL PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      Maurits Wondergem, Friso M. van der Zant, Wouter A.M. Broos and Remco J.J. Knol
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1422-1429; DOI: https://doi.org/10.2967/jnumed.120.258574

  24. Brouwer, Oscar R.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  25. Buck, Andreas K.

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  26. Buckle, Tessa A.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

C

  1. Calais, Jeremie

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  2. Carnevale, Aldo

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  3. Chakhoyan, Ararat

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  4. Cheng, Yuejuan

    1. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of <sup>68</sup>Ga-NODAGA-LM3 and <sup>68</sup>Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096

  5. Cheon, Gi Jeong

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  6. Cho, Steve Y.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  7. Clyne, Marguerite

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  8. Cohrs, Susan

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  9. Collet, Solène

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  10. Constans, Jean-Marc

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  11. Czernin, Johannes

    1. Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics
      Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483; DOI: https://doi.org/10.2967/jnumed.121.262566
    2. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    3. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

D

  1. Dahlbom, Magnus

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  2. Daldrup-Link, Heike E.

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  3. Davidzon, Guido

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  4. Deberle, Luisa M.

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  5. Dell’Oglio, Paolo

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  6. Delpassand, Ebrahim

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  7. Derlon, Jean-Michel

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  8. Donswijk, Maarten

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  9. Duell, Johannes

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

E

  1. Eder, Ann-Christin

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  2. Eder, Matthias

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  3. Eiber, Matthias

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  4. Eilert-Micus, Christina

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  5. Einsele, Herrmann

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  6. Eisenberger, Mario A.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  7. Emmenegger, Urban

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  8. Esfandiari, Rouzbeh

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

F

  1. Fang, Hsin-Yu

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

  2. Fendler, Wolfgang P.

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  3. Franc, Benjamin Lewis

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  4. Fu, Wei

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

G

  1. Gafita, Andrei

    1. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  2. Gardner, Linda

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  3. Gartmann, Jeannine

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  4. Gatidis, Sergios

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  5. Giganti, Melchiore

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  6. Gorin, Michael A.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  7. Gosa, Laura

    1. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  8. Gracheva, Nadezda

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  9. Grimm, Jan

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  10. Grivas, Nikos

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  11. Grogan, Tristan

    1. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  12. Grundler, Pascal V.

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  13. Guillamo, Jean-Sébastien

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  14. Guillouet, Stéphane

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  15. Gupta, Pawan

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  16. Guzik, Patrycja

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760

H

  1. Haberkorn, Uwe

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  2. Hasegawa, Sumitaka

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  3. Hatt, Mathieu

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  4. Hawk, K. Elizabeth

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  5. He, Beilei

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543

  6. Henry, Kelly E.

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  7. Heo, Gyu Seong

    1. The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease
      Gyu Seong Heo, Lanlan Lou, Deborah Sultan and Yongjian Liu
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1341-1346; DOI: https://doi.org/10.2967/jnumed.120.255539

  8. Herrmann, Ken

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  9. Hope, Thomas A.

    1. RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials
      Amir Iravani and Thomas A. Hope
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1438-1439; DOI: https://doi.org/10.2967/jnumed.121.262602
    2. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  10. Hotte, Sebastien

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  11. Huo, Li

    1. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of <sup>68</sup>Ga-NODAGA-LM3 and <sup>68</sup>Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096

I

  1. Iagaru, Andrei

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  2. Im, Hyung-Jun

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  3. Imperiale, Alessio

    1. Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?
      Alessio Imperiale, Leah Meuter, Karel Pacak and David Taïeb
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1347-1348; DOI: https://doi.org/10.2967/jnumed.121.262140

  4. Iravani, Amir

    1. RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials
      Amir Iravani and Thomas A. Hope
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1438-1439; DOI: https://doi.org/10.2967/jnumed.121.262602

J

  1. Jeong, Chang Wook

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  2. Jeong, Jae Min

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  3. Jia, Ru

    1. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of <sup>68</sup>Ga-NODAGA-LM3 and <sup>68</sup>Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
      Wenjia Zhu, Yuejuan Cheng, Ru Jia, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao and Li Huo
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1398-1405; DOI: https://doi.org/10.2967/jnumed.120.253096

  4. Johnson, B. Jake

    1. Open Access
      18F-FDG–Avid Axillary Lymph Nodes After COVID-19 Vaccination
      B. Jake Johnson, Kathryn M. Van Abel, Daniel J. Ma and Derek R. Johnson
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483-1484; DOI: https://doi.org/10.2967/jnumed.121.262108

  5. Johnson, Derek R.

    1. Open Access
      18F-FDG–Avid Axillary Lymph Nodes After COVID-19 Vaccination
      B. Jake Johnson, Kathryn M. Van Abel, Daniel J. Ma and Derek R. Johnson
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483-1484; DOI: https://doi.org/10.2967/jnumed.121.262108

  6. Juergens, Rosalyn

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

K

  1. Kalthoff, Holger

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  2. Kanda, Hiroaki

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  3. Kang, Keon Wook

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  4. Kapoor, Anil

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  5. Karakullukçu, Baris

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  6. Kim, Chun K.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  7. Kim, Jihyun

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  8. Kircher, Malte

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  9. Kiru, Louise

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  10. Klassen, Philipp

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  11. Klein-Scory, Susanne

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  12. KleinJan, Gijs H.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  13. Klop, W. Martin C.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  14. Knol, Remco J.J.

    1. Matched-Pair Comparison of <sup>18</sup>F-DCFPyL PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
      Maurits Wondergem, Friso M. van der Zant, Wouter A.M. Broos and Remco J.J. Knol
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1422-1429; DOI: https://doi.org/10.2967/jnumed.120.258574

  15. Kodaira, Satoshi

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  16. Kopka, Klaus

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  17. Köster, Ulli

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  18. Krummenast, Franziska

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  19. Kulkarni, Harshad R.

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  20. Kusumoto, Tamon

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  21. Kwak, Cheol

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

L

  1. Laffon, Eric

    1. Specific and Nonspecific Uptake in Quantitative 89Zr-Immuno-PET
      Eric Laffon and Roger Marthan
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1484-1485; DOI: https://doi.org/10.2967/jnumed.121.262065

  2. Laidley, David

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

  3. Lapa, Constantin

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  4. Lechapt-Zalcman, Emmanuèle

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  5. Leeuwen, Fijs Van

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  6. Leotta, Karin

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  7. Lewis, Jason S.

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  8. Li, Huizi Keiko

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  9. Liang, Tie

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  10. Liu, Amy

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

  11. Liu, Yongjian

    1. The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease
      Gyu Seong Heo, Lanlan Lou, Deborah Sultan and Yongjian Liu
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1341-1346; DOI: https://doi.org/10.2967/jnumed.120.255539

  12. Lok, Vincent

    1. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  13. Lou, Lanlan

    1. The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease
      Gyu Seong Heo, Lanlan Lou, Deborah Sultan and Yongjian Liu
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1341-1346; DOI: https://doi.org/10.2967/jnumed.120.255539

  14. Lubanovic, Matthew

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

M

  1. Ma, Daniel J.

    1. Open Access
      18F-FDG–Avid Axillary Lymph Nodes After COVID-19 Vaccination
      B. Jake Johnson, Kathryn M. Van Abel, Daniel J. Ma and Derek R. Johnson
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1483-1484; DOI: https://doi.org/10.2967/jnumed.121.262108

  2. Mack, Kyeara N.

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  3. Maietti, Elisa

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  4. Mallak, Nadine

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  5. Marchetti, Lara

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  6. Markowski, Mark C.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  7. Marthan, Roger

    1. Specific and Nonspecific Uptake in Quantitative 89Zr-Immuno-PET
      Eric Laffon and Roger Marthan
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1484-1485; DOI: https://doi.org/10.2967/jnumed.121.262065

  8. Mazzone, Elio

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  9. Merlo, Annalisa

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  10. Metser, Ur

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

  11. Meuter, Leah

    1. Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?
      Alessio Imperiale, Leah Meuter, Karel Pacak and David Taïeb
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1347-1348; DOI: https://doi.org/10.2967/jnumed.121.262140

  12. Millo, Corina

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  13. Minegishi, Katsuyuki

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  14. Mittra, Erik

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  15. Moradi, Farshad

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  16. Morokoshi, Yukie

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  17. Müller, Cristina

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760
    2. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  18. Müller, Dirk

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  19. Myrehaug, Sten

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

N

  1. Nagatsu, Kotaro

    1. Utility of <sup>211</sup>At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
      Huizi Keiko Li, Yukie Morokoshi, Satoshi Kodaira, Tamon Kusumoto, Katsuyuki Minegishi, Hiroaki Kanda, Kotaro Nagatsu and Sumitaka Hasegawa
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1468-1474; DOI: https://doi.org/10.2967/jnumed.120.249300

  2. Nakamoto, Ryusuke

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  3. Nguyen, Judy

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  4. Nguyen, Kathleen

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  5. Nieweg, Omgo E.

    1. Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region
      Danique M.S. Berger, Nynke S. van den Berg, Vincent van der Noort, Bernies van der Hiel, Renato A. Valdés Olmos, Tessa A. Buckle, Gijs H. KleinJan, Oscar R. Brouwer, Lenka Vermeeren, Baris Karakullukçu, Michiel W.M. van den Brekel, Bart A. van de Wiel, Omgo E. Nieweg, Alfons J.M. Balm, Fijs W.B. van Leeuwen and W. Martin C. Klop
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1357-1362; DOI: https://doi.org/10.2967/jnumed.120.246819

  6. Notni, Johannes

    1. PSMA-Targeted Therapeutics: A Tale About Law and Economics
      Johannes Notni
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1482; DOI: https://doi.org/10.2967/jnumed.121.262308

O

  1. Ogirala, Anuja

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  2. Ortega, Claudia

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

P

  1. Pacak, Karel

    1. Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?
      Alessio Imperiale, Leah Meuter, Karel Pacak and David Taïeb
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1347-1348; DOI: https://doi.org/10.2967/jnumed.121.262140

  2. Pappas, Virginia

    1. State of the Society: SNMMI Thrives Despite COVID-19 Challenges
      Virginia Pappas
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 17N;

  3. Parihar, Ashwin Singh

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  4. Park, Sonya

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  5. Pellegrino, Fabio

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  6. Perrio, Cécile

    1. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, <sup>18</sup>F-FMISO PET, and <sup>18</sup>F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Open Access
      Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
      Solène Collet, Jean-Sébastien Guillamo, David Hassanein Berro, Ararat Chakhoyan, Jean-Marc Constans, Emmanuèle Lechapt-Zalcman, Jean-Michel Derlon, Mathieu Hatt, Dimitris Visvikis, Stéphane Guillouet, Cécile Perrio, Myriam Bernaudin and Samuel Valable
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1349-1356; DOI: https://doi.org/10.2967/jnumed.120.249524

  7. Perrucci, Luca

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  8. Pienta, Kenneth J.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  9. Poel, Henk van der

    1. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer
      Elio Mazzone, Paolo Dell’Oglio, Nikos Grivas, Esther Wit, Maarten Donswijk, Alberto Briganti, Fijs Van Leeuwen and Henk van der Poel
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1363-1371; DOI: https://doi.org/10.2967/jnumed.120.259788

  10. Pomper, Martin G.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  11. Prakash, Sneha

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  12. Prasad, Kalpna

    1. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
      Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512

  13. Prigent, Alain

    1. Amnon (Amy) Piepsz, MD (1938–2021)
      Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;

  14. Pröhl, Michael

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

Q

  1. Qi, Jing

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  2. Quon, Andrew

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

R

  1. Rambaldi, Ilaria

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  2. Ranganathan, David

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  3. Rasche, Leo

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  4. Rauert-Wunderlich, Hilka

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  5. Reader, Andrew J.

    1. Artificial Intelligence for PET Image Reconstruction
      Andrew J. Reader and Georg Schramm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1330-1333; DOI: https://doi.org/10.2967/jnumed.121.262303

  6. Reddy, Sunil Arani

    1. Prognostic Value of Bone Marrow Metabolism on Pretreatment <sup>18</sup>F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Prognostic Value of Bone Marrow Metabolism on Pretreatment 18F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
      Ryusuke Nakamoto, Lisa C. Zaba, Tie Liang, Sunil Arani Reddy, Guido Davidzon, Carina Mari Aparici, Judy Nguyen, Farshad Moradi, Andrei Iagaru and Benjamin Lewis Franc
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1380-1383; DOI: https://doi.org/10.2967/jnumed.120.254482

  7. Reid, Colm J.

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  8. Ring, Janine

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  9. Roscher, Mareike

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  10. Rosenwald, Andreas

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  11. Rowe, Steven P.

    1. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
      Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069

  12. Rydén, Tobias

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  13. Ryoo, Hyun Gee

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

S

  1. Samnick, Samuel

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  2. Schaefferkoetter, Josh

    1. Quantitative <sup>68</sup>Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE
      Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
      Claudia Ortega, Rebecca K.S. Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu and Ur Metser
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1406-1414; DOI: https://doi.org/10.2967/jnumed.120.256727

  3. Schäfer, Martin

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  4. Schibli, Roger

    1. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy
      Patrycja Guzik, Hsin-Yu Fang, Luisa M. Deberle, Martina Benešová, Susan Cohrs, Silvan D. Boss, Simon M. Ametamey, Roger Schibli and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1475-1481; DOI: https://doi.org/10.2967/jnumed.120.255760
    2. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  5. Schirbel, Andreas

    1. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
      Johannes Duell, Franziska Krummenast, Andreas Schirbel, Philipp Klassen, Samuel Samnick, Hilka Rauert-Wunderlich, Leo Rasche, Andreas K. Buck, Hans-Jürgen Wester, Andreas Rosenwald, Herrmann Einsele, Max S. Topp, Constantin Lapa and Malte Kircher
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1415-1421; DOI: https://doi.org/10.2967/jnumed.120.257279

  6. Schmidt, Jana

    1. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
      Ann-Christin Eder, Martin Schäfer, Jana Schmidt, Ulrike Bauder-Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka and Matthias Eder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1461-1467; DOI: https://doi.org/10.2967/jnumed.120.248443

  7. Schmiegel, Wolff

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  8. Schöder, Heiko

    1. 2021 SNMMI Highlights Lecture: Oncology and Therapy, Part 1
      Heiko Schöder
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 9N-15N;

  9. Schramm, Georg

    1. Artificial Intelligence for PET Image Reconstruction
      Andrew J. Reader and Georg Schramm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1330-1333; DOI: https://doi.org/10.2967/jnumed.121.262303

  10. Schuchardt, Christiane

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  11. Shaffer, Travis M.

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  12. Singh, Aviral

    1. First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC
      First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC
      Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen and Cristina Müller
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1391-1397; DOI: https://doi.org/10.2967/jnumed.120.258376

  13. Sipos, Bence

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  14. Sitek, Barbara

    1. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
      Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776

  15. Slavik, Roger

    1. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  16. States, Lisa

    1. PET/MRI Improves Management of Children with Cancer
      Lucia Baratto, K. Elizabeth Hawk, Lisa States, Jing Qi, Sergios Gatidis, Louise Kiru and Heike E. Daldrup-Link
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1334-1340; DOI: https://doi.org/10.2967/jnumed.120.259747

  17. Suh, Minseok

    1. Head-to-Head Comparison of <sup>68</sup>Ga-NOTA (<sup>68</sup>Ga-NGUL) and <sup>68</sup>Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
      Minseok Suh, Hyung-Jun Im, Hyun Gee Ryoo, Keon Wook Kang, Jae Min Jeong, Sneha Prakash, Sanjana Ballal, Madhav P. Yadav, Chandrasekhar Bal, Chang Wook Jeong, Cheol Kwak and Gi Jeong Cheon
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1457-1460; DOI: https://doi.org/10.2967/jnumed.120.258434

  18. Sultan, Deborah

    1. The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease
      Gyu Seong Heo, Lanlan Lou, Deborah Sultan and Yongjian Liu
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1341-1346; DOI: https://doi.org/10.2967/jnumed.120.255539

T

  1. Taïeb, David

    1. Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?
      Alessio Imperiale, Leah Meuter, Karel Pacak and David Taïeb
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1347-1348; DOI: https://doi.org/10.2967/jnumed.121.262140

  2. Taylor, Andrew

    1. Amnon (Amy) Piepsz, MD (1938–2021)
      Alain Prigent, M. Donald Blaufox, Andrew Taylor and Naomi Alazraki
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 16N;

  3. Thin, Pan

    1. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)
      Jeremie Calais, Johannes Czernin, Pan Thin, Jeannine Gartmann, Kathleen Nguyen, Wesley R. Armstrong, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, Magnus Dahlbom, Beilei He, Rouzbeh Esfandiari, David Ranganathan, Ken Herrmann, Matthias Eiber, Wolfgang P. Fendler and Ebrahim Delpassand
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1447-1456; DOI: https://doi.org/10.2967/jnumed.121.262543
    2. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
      Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982

  4. Tilli, Massimo

    1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of <sup>18</sup>F-FDG–Avid Lymphomas: A Prospective Study
      Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of 18F-FDG–Avid Lymphomas: A Prospective Study
      Lara Marchetti, Luca Perrucci, Fabio Pellegrino, Luca Baroni, Annalisa Merlo, Massimo Tilli, Ilaria Rambaldi, Elisa Maietti, Aldo Carnevale, Mirco Bartolomei and Melchiore Giganti
      Journal of Nuclear Medicine October 1, 2021, 62 (10) 1372-1379; DOI: https://doi.org/10.2967/jnumed.120.259242

  5. Topp, Max S.